European Chemicals Hangover Is Coming, Cyclical Names Should De-risk

Overview

This is a J.P. Morgan morning-call style comment on the European industrials sector, centered on European chemicals, Stellantis' capital markets day, and Hexagon's post-spin-off valuation. The main line is that the market had previously expected chemical stocks to benefit from the Middle East conflict, but recent data suggest the actual tailwind may be weaker and already fading; after a possible short-term earnings resilience in 2Q, investors will refocus on the weak earnings outlook for 2H26 and 2027, as well as structural pressures from significant overcapacity in China and intensifying competition from Asian producers.

Core views

The core view is to turn defensive on diversified and cyclical chemical stocks, especially BASF, whose valuation remains rich, cash flow yield is low, and ROIC is weak, hence its placement on Negative Catalyst Watch; the downgrades on Evonik, Arkema and IMCD reflect industry fundamentals and valuation risk. At the same time, the report remains selectively constructive: Novonesis retains an OW rating thanks to biofuel demand and high-quality organic growth, while Clariant is upgraded to OW on discounted valuation and its higher-quality specialty chemicals profile. In autos, Stellantis' targets are above parts of the market consensus, but the key issue is whether free cash flow can turn positive in 2027. In industrial technology, Hexagon's post-spin-off RemainCo is viewed as expensive, with the short thesis based on lagging consensus expectations and peer multiple comparisons.

Analysis framework

The report combines event-driven analysis with relative valuation: on one hand tracking the Middle East conflict, energy prices, Chinese chemical prices and 2Q earnings catalysts; on the other comparing company guidance, Bloomberg consensus, historical valuation ranges, peer valuation bands and free cash flow targets to judge near-term catalysts and medium-term earnings quality.

Methodology notes

• Sector cycle and structural supply-demandFading cyclical tailwinds and overcapacity framework

  Short-term geopolitical tailwinds may not offset long-term overcapacity

  The report points out that even as the Middle East conflict continues, Chinese diversified chemical prices are already under pressure, indicating that supply-demand and competitive pressures are more dominant and investors may no longer simply extrapolate the strength of 2Q earnings.

• Valuation and catalystsNegative Catalyst Watch and relative valuation

  A disconnect between valuation and fundamentals can amplify downside risk around earnings

  BASF's FY26/27E EV/EBITDA of about 8.0x/8.5x and P/E of about 18x/21x are above what its earnings quality and cash flow profile can support, which is why it was placed on Negative Catalyst Watch ahead of 2Q results.

• Company event analysisCMD target versus consensus analysis

  Capital markets day targets should be validated against consensus and the cash flow path

  Stellantis set a plan for 2028 revenue of €175bn and a 5% margin, above Bloomberg consensus of €170bn and about 4% margin, but the report emphasizes that the more important issue is near-term free cash flow improvement and the pace of North American volume recovery.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• BASF

  Negative example in European diversified chemicals

  Strengths

  A large integrated chemical platform that may benefit from short-term pricing or 2Q earnings resilience.

  Weaknesses

  Expensive valuation, low FY26/27E FCF yield, post-tax ROIC around 4-5%, and exposure to China's overcapacity and competitive pressure.

  Comparison

  The valuation is seen as disconnected from its historical range and current fundamentals.

  Risks

  2H26 earnings below consensus, market refocusing on structural challenges after 2Q results, restructuring costs and potential impairments.

• Evonik / Arkema / IMCD

  Chemical names downgraded to UW

  Strengths

  All are within the European chemicals coverage universe and have cyclicality if the sector recovers.

  Weaknesses

  The report sees insufficient industry tailwinds and downward pressure on earnings and valuations.

  Comparison

  More exposed to cycle and competitive pressure, and less attractive than selective long names such as Novonesis and Clariant.

  Risks

  Weak demand, intensifying Asian competition, and downward revisions to 2H26 and 2027 earnings expectations.

• Clariant

  Selective long upgraded to OW

  Strengths

  The report sees its discounted valuation as a more attractive entry point, along with higher-quality specialty chemicals attributes.

  Weaknesses

  It had previously been screened as a relative loser in the Middle East conflict scenario.

  Comparison

  Compared with some diversified chemical names, its valuation discount and business quality are more attractive.

  Risks

  If industry demand keeps weakening or specialty product competition intensifies, valuation recovery could be delayed.

• Novonesis

  Maintained OW and seen as a medium-term beneficiary

  Strengths

  Top-tier structural organic growth, margins and underlying ROIC; biofuels account for about 15% of the mix and may benefit from emerging markets' reduced reliance on fossil fuels.

  Weaknesses

  The share price has materially underperformed over the past year and the valuation has de-rated.

  Comparison

  Compared with cyclical chemical names, its growth quality and structural drivers are more pronounced.

  Risks

  Biofuel demand may take longer than expected to materialize, or geopolitical demand shifts may be insufficient.

• Stellantis

  Company for CMD and financial target monitoring

  Strengths

  The company outlined a regional execution framework and an industrial plan to improve earnings and cash flow, with FY28 revenue and margin targets above consensus.

  Weaknesses

  Automotive industry challenges are unprecedented, some regional targets are aggressive, and market demand may be flat.

  Comparison

  The company aims for FY28 revenue of €175bn and a 5% margin, above Bloomberg consensus of €170bn and about 4% margin.

  Risks

  Free cash flow improvement may fall short, North American production recovery may be insufficient, and regional margin targets may not be executed.

• Hexagon RemainCo

  Industrial technology name with expensive post-spin-off valuation

  Strengths

  The spin-off gives the business a clearer structure, and the market still assigns a high valuation.

  Weaknesses

  Consensus expectations may lag and be too high; 22x EV/EBITAC is expensive versus most Swedish industrial peers.

  Comparison

  Most Swedish industrial peers trade around 16-20x, ABB around 24x; the commentary believes 20x is more reasonable, implying about SEK76.

  Risks

  If RemainCo earnings are higher than desk estimates or the market awards a higher quality premium, the short thesis could be challenged.

Key data

• BASF valuationFY26/27E EV/EBITDA 8.0x/8.5x; FY26/27E P/E 18x/21x; FCF yield 1%/3%; after-tax ROIC around 4-5%The report believes this valuation does not fit the challenged fundamentals.
• Cyclical chemical stocks YTD performanceMost are up 15-40%Despite a still challenging structural outlook, share prices have already risen sharply.
• Stellantis FY28 target vs consensusCompany plans revenue of €175bn and a 5% margin; Bloomberg consensus is revenue of €170bn and margin of about 4%The target is above consensus, but execution and free cash flow are key.
• Stellantis cash flow targetsPositive industrial free cash flow in 2027; positive group free cash flow in 2028The report sees the short-term free cash flow path as the key market focus.
• Hexagon RemainCo valuationAbout SEK84 per share implies roughly 22x EV/EBITAC; 20x multiple implies about SEK76The commentary believes consensus expectations are too high and the RemainCo valuation is expensive relative to Swedish industrial peers.
• Commodity price snapshotEU Gas $48 (-2.3%); Brent $102.6 (-2.3%); WTI $97.7 (-1.3%); Gold $4544 (+0.1%); Copper LME Spot $13456 (-1%)Displayed as industrial and macro background data.

Impact & implications

For portfolios, the implication is that the European chemicals sector should not keep chasing short-term conflict-driven trading gains; exposure to richly valued diversified chemical names with higher earnings downgrade risk should be reduced, while selective allocations should be maintained to companies with structural growth, valuation discounts, or specialty-chemical quality characteristics. For autos, Stellantis' medium-term targets offer an upside narrative, but they need validation from cash flow and North American production recovery. For industrial technology, the post-spin-off valuation reset at Hexagon may create short opportunities or relative-value trades.

Risks

• The direction of the Middle East conflict is hard to judge; if it intensifies and materially pushes up chemical prices, the short-term industry tailwind could exceed the report's expectations.
• If 2Q results are broadly stronger than expected, market repricing of structural pressure in 2H26 and 2027 could be delayed.
• The intensity of China and Asian capacity competition, European demand, and energy price changes could alter the chemical earnings path.
• Stellantis' medium-term targets carry execution risk, especially around North American production recovery, regional margins, and free cash flow generation.
• Hexagon's post-spin-off valuation view depends on desk estimates and the pace of consensus revisions; if consensus is corrected quickly or Octave is valued higher, the trade conclusion could change.

What to watch

• BASF 2Q results, with the report citing July 29 as the key date.
• Wacker 2Q results, with the report citing June 30 as the key date.
• Chinese diversified chemical prices, European chemical demand, and the intensity of competition in Asian specialty products.
• Whether Novonesis' biofuel-related demand is strengthened by geopolitics and energy security concerns.
• Quarterly progress on North American production recovery, industrial free cash flow and group free cash flow at Stellantis.
• Post-spin-off consensus earnings revisions for Hexagon RemainCo, peer valuation ranges and Octave implied valuation.